No profile data available.
Nkarta, Inc. (NKTX) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in South San Francisco, United States, with about 106 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$104.08 million. Its market capitalization was $161.16 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
Nkarta reported $0 in revenue for fiscal year 2025.
$161.16 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Cabaletta Bio, Inc. (CABA), Century Therapeutics, Inc. (IPSC), Cue Biopharma, Inc. (CUE), Immunic, Inc. (IMUX).